SCHEMBL15079559

SCHEMBL15079559

CN(C(=O)OCc1ccccc1)C1(CO)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
RORC P51449 2/20 0.41
ABCB1 P08183 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
CCR6 P51684 1/20 0.40
PAX8 Q06710 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19031404 0.94 SIGMAR1 (0.45) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL16219337 0.88 ALDH1A1 (0.47) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL15079558 0.87 ALDH1A1 (0.46) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL13211826 0.86 ALDH1A1 (0.45) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL19031171 0.86 KMT2A (0.40) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL26996327 0.82 ALDH1A1 (0.44) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL15079561 0.81 ALDH1A1 (0.44) ALDH1A1MAPTHPGDSIGMAR1RORC
SCHEMBL18765832 0.81 ALDH1A1 (0.49) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL20582129 0.81 ALDH1A1 (0.49) ALDH1A1MAPTHPGDSIGMAR1MAPK1
SCHEMBL15079560 0.80 L3MBTL1 (0.45) ALDH1A1MAPTHPGDSIGMAR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017109088-A1 PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE SAVIRA PHARMACEUTICALS GMBH (AT) 2017-06-29 WO disclosed
EP-2763998-B1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2016-04-27 EP disclosed
US-9216997-B2 Tri-heterocyclic derivatives, preparation process and uses thereof SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2015-12-22 US disclosed
US-9216997-B2 Tri-heterocyclic derivatives, preparation process and uses thereof SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2015-12-22 US disclosed
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2014-11-06 US disclosed
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2014-11-06 US disclosed
WO-2013091502-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329800-A1 TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF MAP3K15, MAP3K1, MAP3K5 ALDH1A1 2288/4885MAPT 2207/4885HPGD 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.